

more effectively against malaria, and thereby reduce the continuing health threat of this potentially lethal disease to military forces.

References

1. Rieckmann KH, Yeo AET, Davis DR, et al. Recent military experience with malaria prophylaxis. *Med J Aust* 1993; 158: 446-449.
2. Rieckmann KH, Trenholme GM, Williams RL, et al. Prophylactic activity of mefloquine hydrochloride (WR 142490) in drug resistant malaria. *Bull WHO* 1974; 51: 375-377.
3. Centers for Disease Control. Health information for international travel, 1999-2000. Atlanta: CDC; 1999.
4. Baird JK, Hoffman SL. Prevention of malaria in travelers. *Med Clin North Am* 1999; 83: 923-944.
5. Schlagenhauf P. Mefloquine for malaria chemoprophylaxis 1992-1998: A review. *J Travel Med* 1999; 6: 122-133.
6. Steffen R, Fuchs E, Schildknecht J, et al. Mefloquine compared with other malaria chemoprophylactic regimens in tourists visiting East Africa. *Lancet* 1993; 341: 1299-1303.
7. Canfield CJ, Boudreau EF, Alstatt LB, et al. Worldwide controlled clinical trials with atovaquone and proguanil for treatment of *Plasmodium falciparum* malaria. *Am J Trop Med Hyg* 1995; 53 Suppl: 87.
8. Milhous WK, Brueckner RP, Theoharides AD, et al. Preclinical efficacy of WR 238605. In: Program and abstracts of the 31st Interscience Conference on Antimicrobial Agents and Chemotherapy. American Society of Microbiology, Washington, DC, USA; 1992. Abstract 376.
9. Milhous WK, Theoharides AD, Schuster BG, et al. New alternatives to primaquine. In: Program and abstracts of the XIIth International Congress for Tropical Medicine and Malaria. Amsterdam, the Netherlands; 1988. Abstract FrS-12-4.
10. Cooper RD, Milhous WK, Rieckmann KH. The efficacy of WR 238605 against the blood stages of a chloroquine resistant strain of *Plasmodium vivax*. *Trans R Soc Trop Med Hyg* 1994; 88: 691-692.
11. Kyle DE. In vitro antimalarial activity of etaquine (WR 238605). In: Symposium on Etaquine held in association with the 46th Annual Meeting of the American Society of Tropical Medicine and Hygiene; 1997 Dec 7-11; Florida, USA.
12. Coleman RE, Clavin AM, Milhous WK. Gametocytocidal and sporontocidal activity of antimalarials against *Plasmodium berghei* ANKA in ICR mice and *Anopheles stephensi* mosquitoes. *Am J Trop Med Hyg* 1992; 46: 169-182.
13. Brueckner RP, Coster T, Wesche DL, et al. Prophylaxis of *Plasmodium falciparum* infection in a human challenge model with WR 238605, a new 8-aminoquinoline antimalarial. *Antimicrob Agents Chemother* 1998; 42: 1293-1294.
14. Brueckner RP, Lasseter KC, Lin ET, et al. First-time-in-humans safety and pharmacokinetics of WR 238605, a new antimalarial. *Am J Trop Med Hyg* 1998; 58: 645-649.
15. Idowu OR, Peggins JO, Brewer TG, et al. Metabolism of a candidate 8-aminoquinoline antimalarial agent. *Drug Metab Dispos* 1995; 23: 1-17.
16. Shanks D. Etaquine (WR 238605) for the prophylaxis of *Plasmodium falciparum* malaria. In: Symposium on Etaquine held in association with the 46th Annual Meeting of the American Society of Tropical Medicine and Hygiene; 1997 Dec 7-11; Florida, USA.
17. Lell B, Faucher J-F, Missinou MA, et al. Malaria chemoprophylaxis with tafenoquine: a randomised study. *Lancet* 2000; 355: 2041-2045.
18. Hale BR, Owusu-Agyei S, Koram KA, et al. A randomized, double-blinded, placebo-controlled trial of tafenoquine for prophylaxis against *Plasmodium falciparum* in Ghana [abstract]. *Am J Trop Med Hyg* 2000; 62: 139-140.
19. Walsh DS, Eamsila C, Sasiprapha T, et al. Randomised, double-blind, placebo controlled evaluation of monthly WR 238605 (tafenoquine) for prophylaxis of *Plasmodium falciparum* and *Plasmodium vivax* in Royal Thai Army Soldiers [abstract]. *Am J Trop Med Hyg* 1999; 61: 502.
20. Walsh DS, Looareesuwan S, Wilairatana P, et al. Randomized dose-ranging study of the safety and efficacy of WR 238605 (tafenoquine) in the prevention of relapse of *Plasmodium vivax* malaria in Thailand. *J Infect Dis* 1999; 180: 1282-1287.
21. Clyde DF. Clinical problems associated with the use of primaquine as a tissue schizonticidal and gametocytocidal drug. *Bull WHO* 1981; 59: 391-395.
22. Rieckmann KH. The future of etaquine. In: Symposium on etaquine held in association with the 46th Annual Meeting of the American Society of Tropical Medicine and Hygiene; 1997 Dec 7-11; Florida, USA. □

Book review

Neurosurgery in the tropics

Geoffrey V Rosenfeld and David A K Watters. **Neurosurgery in the tropics. A practical approach to common problems.** Melbourne: Macmillan Education, 2000. \$63. ISBN 0 33 68412 5

MANY WHO PRACTISE MEDICINE outside major centres are confronted with inescapable patient management decisions with potential neurological consequences. Not all neurosurgery can be conducted by full-time neurosurgeons. This new book is a practical guide for doctors operating outside centres with a practising neurosurgeon, written by authors with extensive experience under difficult circumstances in Australia, Papua New Guinea, Zimbabwe, Zambia and other developing countries. It is a splendid, clearly written diagnostic guide for those in the field. It covers the crucial questions of clinical assessment in the potential neurosurgical context, and will be an aid for those who have to decide on aeromedical evacuations, sum-

moning of trauma teams or (most difficult of all) when not to operate.

The book describes details of common neurosurgical operations, particularly emergency operations to preserve life or brain function, in the clearest terms. There are excellent sections on head injury in the context of developing countries, congenital malformations involving the cranespinal axis, diagnosis of brain death, neurorehabilitation and medicolegal issues.

I commend the book to all who work in tropical settings, refugee camps, or in outback or other isolated medical practices, and to all those doctors who may go on operational deployments with the Defence Health Service.

Major General John Pearn, AM, RFD (Rtd)